Carboplatin
- Generic Name
- Carboplatin
- Brand Names
- Paraplatin
- Drug Type
- Small Molecule
- Chemical Formula
- C6H12N2O4Pt
- CAS Number
- 41575-94-4
- Unique Ingredient Identifier
- BG3F62OND5
- Background
Carboplatin is an organoplatinum antineoplastic alkylating agent used in the treatment of advanced ovarian carcinoma. Early clinical studies of carboplatin were performed in 1982. Carboplatin was developed as an analog of cisplatin with reduced nephrotoxicity and vomiting.
Carboplatin was granted FDA approval on 3 March 1989.
- Indication
Carboplatin is indicated in combination with an established combination of chemotherapeutic agents for the initial treatment of advanced ovarian carcinoma. Carboplatin is also indicated for the palliative treatment of ovarian carcinoma, recurrent after prior chemotherapy.
- Associated Conditions
- Advanced Cervical Cancer, Advanced Endometrial Cancer, Advanced Esophageal Cancers, Advanced Head and Neck Cancer, Advanced Melanoma, Advanced Non-Small Cell Lung Cancer (NSCLC), Advanced Ovarian Carcinoma, Advanced Sarcoma, Malignant Pleural Mesothelioma (MPM), Merkel Cell Carcinoma, Metastatic Breast Cancer, Refractory Hodgkin Lymphoma, Retinoblastoma, Thymoma, Advanced Bladder cancer, Advanced Small cell lung cancer, Advanced Testicular cancer, Advanced Thymoma, Refractory Non-Hodgkin's lymphoma
- Associated Therapies
- Conditioning regimens for allogeneic stem cell transplantation therapy
Estramustine, Docetaxel, and Carboplatin in Treating Patients With Prostate Cancer That Has Not Responded to Hormone Therapy
- Conditions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-07-18
- Lead Sponsor
- Dana-Farber Cancer Institute
- Registration Number
- NCT00005627
- Locations
- 🇺🇸
Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Combination Chemotherapy Following Surgery in Treating Patients With Urinary Tract Cancer
- Conditions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-07-10
- Lead Sponsor
- Tulane University Health Sciences Center
- Registration Number
- NCT00028860
- Locations
- 🇺🇸
Tulane Cancer Center at Tulane University Hospital and Clinic, New Orleans, Louisiana, United States
Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Older Patients With Refractory or Relapsed Intermediate-Grade Non-Hodgkin's Lymphoma
- Conditions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-07-03
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Registration Number
- NCT00002982
- Locations
- 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
Combination Chemotherapy in Treating Patients With Advanced Bladder or Kidney Cancer
- Conditions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-07-03
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 30
- Registration Number
- NCT00003342
- Locations
- 🇺🇸
New York Weill Cornell Cancer Center at Cornell University, New York, New York, United States
🇺🇸Memorial Sloan-Kettering Cancer Center, New York, New York, United States
Surgery With or Without Chemotherapy in Treating Patients With Stage I Non-small Cell Lung Cancer
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-07-03
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 500
- Registration Number
- NCT00002852
- Locations
- 🇺🇸
Cancer and Leukemia Group B, Chicago, Illinois, United States
UCN-01 and Carboplatin in Treating Patients With Advanced Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-07-01
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 30
- Registration Number
- NCT00036777
- Locations
- 🇺🇸
University of Maryland Greenebaum Cancer Center, Baltimore, Maryland, United States
Combination Chemotherapy With or Without Bone Marrow or Stem Cell Transplantation in Treating Men With Untreated Germ Cell Tumors
- Conditions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-06-26
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 270
- Registration Number
- NCT00002596
- Locations
- 🇺🇸
FirstHealth Moore Regional Hospital, Pinehurst, North Carolina, United States
🇺🇸Arthur G. James Cancer Hospital - Ohio State University, Columbus, Ohio, United States
🇺🇸Louis A. Weiss Memorial Hospital, Chicago, Illinois, United States
Combination Chemotherapy Followed by Bone Marrow Transplantation in Treating Patients With Rare Cancer
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-06-24
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Registration Number
- NCT00002515
- Locations
- 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
Combination Chemotherapy With or Without Amifostine in Treating Young Patients With Liver Cancer
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-06-14
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 277
- Registration Number
- NCT00003994
- Locations
- 🇺🇸
Children's Oncology Group, Arcadia, California, United States
Combination Chemotherapy in Treating Patients With Transitional Cell Cancer of the Urothelium
- Conditions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-06-12
- Target Recruit Count
- 238
- Registration Number
- NCT00014274
- Locations
- 🇳🇱
Academisch Medisch Centrum at University of Amsterdam, Amsterdam, Netherlands
🇧🇪Institut Jules Bordet, Brussels, Belgium
🇳🇱Universitair Medisch Centrum St. Radboud - Nijmegen, Nijmegen, Netherlands
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.